Pfizer Inc. (NYSE:PFE) insider Mikael Dolsten sold 69,699 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the completion of the transaction, the insider now owns 120,784 shares in the company, valued at approximately $4,419,486.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Mikael Dolsten also recently made the following trade(s):
- On Friday, March 2nd, Mikael Dolsten sold 13,986 shares of Pfizer stock. The stock was sold at an average price of $35.85, for a total transaction of $501,398.10.
Pfizer Inc. (PFE) traded down $0.16 on Monday, reaching $36.61. 25,210,000 shares of the company’s stock traded hands, compared to its average volume of 29,020,000. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The company has a market capitalization of $217,930.00, a P/E ratio of 20.92, a PEG ratio of 2.07 and a beta of 0.91.
Pfizer declared that its board has authorized a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were given a $0.34 dividend. The ex-dividend date of this dividend was Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.71%. Pfizer’s dividend payout ratio (DPR) is presently 77.71%.
Several brokerages have recently issued reports on PFE. BMO Capital Markets set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research report on Monday, February 26th. Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. UBS Group set a $42.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Leerink Swann increased their price objective on shares of Pfizer from $35.00 to $38.00 and gave the company a “market perform” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $39.40.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer in the second quarter worth $103,000. Earnest Partners LLC purchased a new stake in shares of Pfizer in the fourth quarter worth $105,000. First Dallas Securities Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth $118,000. Woodard & Co. Asset Management Group Inc. ADV purchased a new stake in shares of Pfizer in the fourth quarter worth $118,000. Finally, Herndon Capital Management LLC purchased a new stake in shares of Pfizer in the second quarter worth $120,000. Institutional investors and hedge funds own 71.41% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/03/12/pfizer-inc-pfe-insider-sells-2550286-41-in-stock.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.